Light the Way™
Detect. Predict. Monitor.
Discover the power of a different perspective
Saving lives through early detection and predictive response.
Molecular diagnostics exists to make the hidden visible.
Our mission is to light the way in which cancer is detected, treated and monitored. Using our patent pending fluorescence technology we diagnose cancer and predict treatment response by measuring Protein-Cross-Sections within body fluids.
While DNA gives information about how people and organisms might develop over their entire lifetimes, proteins give information about how they are actually developing at a specific point in time. Proteins are produced within cells and are the direct, real-time indicators of the state of a biological system.
"If DNA is the script, then proteins are the actors. They bring the story to life"
Clinical application
So why don’t we see more proteomic based diagnostic tests in the clinic? The levels of individual proteins can vary significantly between patients, even for patients with the same disease.
Even if you did find a magical set of proteins that were predictive of disease, the error bars can be so high that it can be difficult to define clear thresholds that can form the basis of a robust test.
Instead we asked
Could we analyse thousands of proteins in a single experiment? Could we find a solution to inter-patient heterogeneity via some robust proteomic profile, an average expression of the proteins in a given biological sample.
Instead of focusing on the proteins themselves, we switched our focus, and quantified their building blocks - taking a high dimensional data set and effectively performing a Fourier transform on a noisy signal.
But even so, would our signal be sufficiently differentiable to distinguish between healthy and disease states?
Our insight
Measuring individual biomarkers isn't needed to diagnose cancer. There is no need to compare individual proteins.
“It’s like a CT scan for your blood,
cross sectional snapshots that together
compose a signature of healthy or disease states - your Proteotype.”
Our vision is to be the SpaceX of Diagnostics
Our unique insight has led us to develop a technology platform that is modular with re-usable core components.
We do not need to develop a new diagnostic target panel for a new indication, reducing cost and time to insight.